Drug analysis

A
B-C
D-F
Drug Analysis
G-L
M-O
P-R
S-T
U-Z

Text search

Sort by Relevance

Click to order products descending

Display 45 Products per page

Sirukumab
Read More
Sirukumab (CNTO 136; Janssen/GlaxoSmithKline) is a human monoclonal antibody interleukin-6 receptor antagonist that is currently in Phase III development for rheumatoid arthritis.
March 24, 2015
Find out more
Sarilumab
Read More
Sarilumab (Sanofi/Regeneron) is a human monoclonal antibody interleukin (IL)-6 receptor antagonist in Phase III development for rheumatoid arthritis.
March 24, 2015
Find out more
Tykerb
Read More
Tykerb (lapatinib; Novartis) is an orally available EGFR (epidermal growth factor receptor) and human epidermal growth factor receptor 2 (HER2) dual tyrosine kinase inhibitor.
March 9, 2015
Find out more
Neratinib
Read More
Neratinib (Puma Biotechnology) is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptor (HER)1, HER2, HER4, and epidermal growth factor receptor kinases.
March 9, 2015
Find out more
Kadcyla
Read More
Kadcyla (ado-trastuzumab emtansine; ImmunoGen/Roche/Chugai) is a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC), which contains the humanized anti-HER2 immunoglobulin G1 Herceptin.
March 9, 2015
Find out more
Zelapar
Read More
Zelapar (selegiline; Valeant) is a novel rapidly disintegrating tablet formulation of the monoamine oxidase B (MAO-B) inhibitor selegiline.
October 24, 2014
Find out more
Cubicin
Read More
Cubicin is a cyclic lipopeptide antibacterial that has a unique mechanism of action. It causes rapid depolarization of the bacterial cell membrane potential upon binding to the membrane.
September 10, 2014
Find out more
Orbactiv
Read More
Orbactiv is a broad-spectrum antibiotic mainly targeting inpatient settings. The drug is a semisynthetic lipoglycopeptide that inhibits bacterial cell wall synthesis by blocking peptidoglycan biosynthesis.
September 10, 2014
Find out more
Delafloxacin
Read More
Delafloxacin is a novel broad-spectrum fluoroquinolone that prevents bacterial DNA synthesis through its equal inhibitory effect against the enzymes topoisomerase II (DNA gyrase) and IV.
September 10, 2014
Find out more
Dalvance
Read More
Dalvance is a second-generation, semi-synthetic lipoglycopeptide antibacterial compound of the same class as vancomycin. The drug inhibits the formation of, and disrupts the integrity of…
September 10, 2014
Find out more
Sivextro
Read More
Sivextro is a second-generation oxazolidinone, while tedizolid phosphate is a prodrug that is cleaved in the bloodstream to the active antibiotic tedizolid. The active moiety tedizolid inhibits bacterial protein synthesis by interacting with the bacterial 23S ribosome initiation complex.
September 10, 2014
Find out more
Vibativ
Read More
Vibativ is a lipoglycopeptide antibiotic that is a semisynthetic derivative of vancomycin. The drug exhibits a dual bactericidal mechanism of action.
September 10, 2014
Find out more
Aplidin
Read More
Aplidin is an intravenous, marine-originated cyclic depsipeptide antitumor agent. The drug, which is

currently synthesized chemically, was originally isolated from the marine tunicate Aplidium albicans

(Cuadrado et al., 2003; PharmaMar, 2014).
September 4, 2014
Find out more
Flolan
Read More
In 1995, GlaxoSmithKline’s Flolan (epoprostenol) became the first therapy to be specifically approved for the orphan disease of pulmonary arterial hypertension (PAH).
June 25, 2014
Find out more
Volasertib
Read More
Volasertib is a polo-like kinase (Plk) inhibitor being developed by Boehringer Ingelheim for the treatment of AML.
April 22, 2014
Find out more
Midostaurin
Read More
Midostaurin is a multiple kinase inhibitor, which interferes with cellular signal transduction pathways. While the drug exhibits efficacy against a number of kinases, its efficacy against FLT3 is of particular relevance to AML.
April 22, 2014
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *